Online Inquiry
NAGA Knockout Cell Line
SPL-02227
| Size | Price |
| 1 Unit | Online Inquiry |
| Description |
|---|
| Frameshift mutation |
| Target Information | |
|---|---|
| Target Name | NAGA |
| Gene Abbr. | NAGA |
| Gene ID | 4668 |
| Full Name | alpha-N-acetylgalactosaminidase |
| Alias | D22S674, GALB |
| Species | Human |
| WT Expression Level | 11.81 TPM (TPM = Transcripts per million; any value less than 3 is considered non-expressing) |
| Introduction | NAGA encodes the lysosomal enzyme alpha-N-acetylgalactosaminidase, which cleaves alpha-N-acetylgalactosaminyl moieties from glycoconjugates. Mutations in NAGA have been identified as the cause of Schindler disease types I and II (type II also known as Kanzaki disease). [provided by RefSeq, Jul 2008]. |
| Product Details | |
|---|---|
| Cell Line Model | HAP1 |
| Genotype | HAP1 cell line, edited by CRISPR/Cas to contain a frameshift mutation in a coding exon of NAGA. |
| Description | Frameshift mutation |
| Parental Cell Line | C631 |
| Handling Specifications | |
|---|---|
| Revival | Rapidly thaw cells in a 37°C water bath. Transfer contents into a tube containing pre-warmed media. Centrifuge cells and seed into 10 mL of pre-warmed media in a 10 cm dish. |
| Culture Medium | IMDM + 10% FCS |
| Growth Properties | Cells are adherent cells that are cultured at 37°C in a humidified atmosphere with 5% CO2. Cells should be passaged every 2-3 days, splitting approximately 1:10-1:20. |
| Freeze Medium | IMDM + 20% FCS + 10% DMSO |
| Biosafety Level | BSL-1 |
| Disclaimer | This product is classified under IATA regulations as a GMMO (genetically modified micro-organism) and will ship as UN3245. If applicable, ensure facility meets all requirements per local and country regulations. |
For research use only. Not intended for any clinical use. No products from CD BioSciences may be resold, modified for resale or used to manufacture commercial products without prior written approval from CD BioSciences.